Share ownership Lonza Group AG

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:13:13 10/07/2026 pm IST			5-day change	1st Jan Change
589.20 ^CHF	+1.13%		+2.93%	+9.89%

02/07	Nona Biosciences And Lonza Enter Strategic Collaboration To Develop Best-In-Class Single-Domain Antibody-Based BBB-Crossing Technology For CNS Diseases	CI
01/07	Lonza Group AG Expands Strategic Collaboration With Leading US Biopharmaceutical Company	CI

Share class: Lonza Group AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	7,02,29,021	6,97,81,055 ( 99.36 %)	3,84,792 ( 0.5479 %)	99.36 %

Major shareholders: Lonza Group AG

Name	Stocks	%	Valuation
Norges Bank Investment Management 2.99 %	20,99,847	2.99 %	1 345 M CHF
Rothschild & Co. Asset Management SCS 0.5561 %	3,90,544	0.5561 %	250 M CHF
LONZA GROUP AG 0.5479 %	3,84,792	0.5479 %	246 M CHF
Rathbones Asset Management Ltd. 0.3543 %	2,48,842	0.3543 %	159 M CHF
Nordea Investment Management AB 0.3006 %	2,11,107	0.3006 %	135 M CHF
Goldman Sachs Asset Management International 0.2737 %	1,92,188	0.2737 %	123 M CHF
Sjunde AP-fonden 0.2283 %	1,60,321	0.2283 %	103 M CHF
Capfi Delen Asset Management NV 0.1973 %	1,38,531	0.1973 %	89 M CHF
Goldman Sachs Asset Management BV 0.1964 %	1,37,901	0.1964 %	88 M CHF
Caixabank Asset Management SGIIC SAU 0.1354 %	95,115	0.1354 %	61 M CHF
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
SBI Funds Management Ltd. (Investment Management) 0.0228 %	1,60,000	0.0228 %	10 M CHF
Torray Investment Partners LLC 0.0132 %	92,468	0.0132 %	6 M CHF
Azimuth Capital Investment Management LLC 0.0122 %	85,415	0.0122 %	5 M CHF
Madison Asset Management LLC 0.00319 %	22,401	0.00319 %	1 M CHF
RhumbLine Advisers LP 0.002039 %	14,323	0.002039 %	917 288 CHF
Henry James International Management, Inc. 0.001059 %	7,440	0.001059 %	476 480 CHF
Accent Capital Management LLC 0.000171 %	1,199	0.000171 %	76 788 CHF
Hantz Financial Services, Inc. 0.000159 %	1,120	0.000159 %	71 728 CHF
NBC Securities, Inc. 0.000113 %	791	0.000113 %	50 658 CHF
Westside Investment Management LLC 0.000043 %	300	0.000043 %	19 213 CHF
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	8.71%
Lonza Group AG	0.55%
Individuals	0.09%
Unknown	90.65%

Based on 1000 largest holdings

Geographical origin of shareholders

Norway	3%
Switzerland	2.03%
United Kingdom	0.8%
France	0.75%
Sweden	0.56%
United States	0.35%
Netherlands	0.25%
India	0.23%
Spain	0.22%
Belgium	0.21%
Germany	0.16%
Italy	0.13%
Canada	0.11%
Ireland	0.11%
Individuals	0.09%
Liechtenstein	0.07%
Luxembourg	0.05%
Austria	0.05%
Taiwan	0.04%
Finland	0.03%
Denmark	0.02%
Japan	0.02%
Hong Kong	0.02%
Australia	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Lonza Group AG is one of the world leaders of the contract development and manufacturing of pharmaceutical and biotechnology products. Net sales break down by family of products and services as follows: - biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.; - synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.; - specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.; - others (3.6%).

Employees

20,000

Sector

Biotechnology & Medical Research

Calendar

22/07 - Earnings release - Q2 2026

More about the company